FCE 23892
Latest Information Update: 30 May 2001
Price :
$50 *
At a glance
- Originator Pharmacia Corporation
- Class Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 02 Sep 1998 No-Development-Reported for Anxiety disorders in Italy (Unknown route)
- 15 Dec 1995 New profile